Dutch multicenter experience using the STENTYS Xposition S self-apposing stent in complex coronary lesions.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
01 Dec 2019
Historique:
received: 19 10 2018
accepted: 01 03 2019
pubmed: 25 3 2019
medline: 2 9 2020
entrez: 24 3 2019
Statut: ppublish

Résumé

The aim is to assess the experience in the Netherlands using the Xposition S self-apposing stent in complex coronary lesions in clinical practice. Treatment of complex coronary lesions could be accompanied with stent sizing difficulties and complications, particularly due to vessel overdilation or stent underexpansion. The self-apposing feature of the Xposition S stent (STENTYS, Paris, France) supports good strut apposition in complex anatomies and allows for an increase in diameter after implantation. In this real-world registry, data from patients treated with Xposition S in four Dutch clinical sites were prospectively collected and analyzed. Any patient suitable for implantation with Xposition S according to current recommendations was enrolled. Primary endpoint was major adverse cardiac events (MACE) at 1 year. Between 2015 and 2018, data from 251 patients were collected. Clinical presentation was an acute coronary syndrome in majority of the patients (76.9%). Main angiographic indications were lesions in aneurysmatic or ectatic vessels (32.3%), thrombus containing lesions (13.1%), and bifurcation/left main stenosis (10.4%). Most of the target lesions (TLs) were classified as AHA/ACC Type C (53.6%). Despite lesion complexity, device was successfully implanted at TL in 96.8%. MACE rate, reported on patients having completed 1-year follow-up (n = 203), was 6.6%, with low rate of definite/probable stent thrombosis (1.0%). In clinical practice of several Dutch sites, STENTYS Xposition S showed good procedural results and low 1-year clinical events rate, despite complex coronary anatomy.

Sections du résumé

OBJECTIVES OBJECTIVE
The aim is to assess the experience in the Netherlands using the Xposition S self-apposing stent in complex coronary lesions in clinical practice.
BACKGROUND BACKGROUND
Treatment of complex coronary lesions could be accompanied with stent sizing difficulties and complications, particularly due to vessel overdilation or stent underexpansion. The self-apposing feature of the Xposition S stent (STENTYS, Paris, France) supports good strut apposition in complex anatomies and allows for an increase in diameter after implantation.
METHODS METHODS
In this real-world registry, data from patients treated with Xposition S in four Dutch clinical sites were prospectively collected and analyzed. Any patient suitable for implantation with Xposition S according to current recommendations was enrolled. Primary endpoint was major adverse cardiac events (MACE) at 1 year.
RESULTS RESULTS
Between 2015 and 2018, data from 251 patients were collected. Clinical presentation was an acute coronary syndrome in majority of the patients (76.9%). Main angiographic indications were lesions in aneurysmatic or ectatic vessels (32.3%), thrombus containing lesions (13.1%), and bifurcation/left main stenosis (10.4%). Most of the target lesions (TLs) were classified as AHA/ACC Type C (53.6%). Despite lesion complexity, device was successfully implanted at TL in 96.8%. MACE rate, reported on patients having completed 1-year follow-up (n = 203), was 6.6%, with low rate of definite/probable stent thrombosis (1.0%).
CONCLUSIONS CONCLUSIONS
In clinical practice of several Dutch sites, STENTYS Xposition S showed good procedural results and low 1-year clinical events rate, despite complex coronary anatomy.

Identifiants

pubmed: 30903739
doi: 10.1002/ccd.28192
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

966-971

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Références

Koch KT, Grundeken MJ, Vos NS, et al. One-year clinical outcomes of the STENTYS Self-Apposing® coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. EuroIntervention. 2015;11:264-271.
IJsselmuiden AJJ, Simsek C, Van Driel AG, et al. Comparison between the STENTYS self-apposing bare metal and paclitaxel-eluting coronary stents for the treatment of saphenous vein grafts (ADEPT trial). Neth Heart J. 2018;26:94-101.
Brugaletta S, Martin-Yuste V, Padró T, et al. Endothelial and smooth muscle cells dysfunction distal to recanalized chronic total coronary occlusions and the relationship with the collateral connection grade. J Am Coll Cardiol Intv. 2012;5:170-178.
Santos MC, Lin T, Barlis P. In-stent restenosis associated with stent malapposition: Seven year optical coherence tomography findings. Int J Cardiol. 2011;147:149-151.
Nakazawa G. Stent thrombosis of drug eluting stent: Pathological perspective. J Cardiol. 2011;58:84-91.
Souteyrand G, Amabile N, Mangin L, et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: Insights from the national PESTO French registry. Eur Heart J. 2016;37:208-1216.
Amoroso G, van Geuns RJ, Spaulding C, et al. Assessment of the safety and performance of the STENTYS self-expanding coronary stent in acute myocardial infarction: Results from the APPOSITION I study. EuroIntervention. 2011;7:428-436.
van Geuns RJ, Tamburino C, Fajadet J, et al. Self-expanding versus balloon-expandable stents in acute myocardial infarction: Results from the APPOSITION II study: Self-expanding stents in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012;5:1209-1219.
Lu H, IJsselmuiden AJ, Grundeken MJ, et al. First-in-man evaluation of the novel balloon delivery system STENTYS Xposition S for the self-apposing coronary artery stent: Impact on longitudinal geographic miss during stenting. EuroIntervention. 2016;11:1341-1345.
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115:2344-2351.
Ng J, Foin N, Ang Y, et al. Over-expansion capacity and stent design model: An update with contemporary DES platforms. Int J Cardiol. 2016;221:171-179.
Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularization (LEADERS): A randomised non-inferiority trial. Lancet. 2008;372:1163-1173.
Danzi GB, Chevalier B, Urban P, et al. Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: The NOBORI 2 study. EuroIntervention. 2012;8:109-116.

Auteurs

Selina Vlieger (S)

Department of Cardiology, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands.

Cihan Simsek (C)

Department of Cardiology, Erasmus Medical Centre, Rotterdam, The Netherlands.

Anaïs Balland (A)

STENTYS, STENTYS SA, Paris, France.

Sami Somi (S)

Department of Cardiology, HAGA Ziekenhuis, Den Haag, The Netherlands.

Gillian Jessurun (G)

Department of Cardiology, Treant Zorggroep, Emmen, The Netherlands.

Giovanni Amoroso (G)

Department of Cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.

Floris Kauer (F)

Department of Cardiology, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands.

Robert-Jan van Geuns (RJ)

Department of Cardiology, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands.

Alexander IJsselmuiden (A)

Department of Cardiology, Amphia Ziekenhuis, Breda, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH